Supplementary Material S3. MSU multivariable logistic regression analysis (entire cohort) including fusion biopsy

Variable	OR (95% CI)	*p-value*
PSAD	2.02 (1.32–3.10)	**0.001**
HT	1.54 (1.17–2.03)	**0.002**
Fusion biopsy	0.58 (0.42–0.81)	**0.001**
Upgrading	1.34 (1.02–1.75)	**0.034**

Table 4 *presents the results of a multivariable logistic regression analysis assessing predictors of pathological upstaging in prostate cancer including fusion biopsy.*

- ***OR (Odds Ratio)*** *– quantifies the strength of association between each variable and the odds of upstaging.*
- ***95% CI (Confidence Interval)*** *– indicates the range within which the true odds ratio is expected to lie with 95% confidence.*
- ***PSAD*** *– prostate-specific antigen density, calculated as serum PSA (ng/mL) divided by prostate volume (cm^3).*
- ***Hypertension (HT)*** *– history of clinically diagnosed arterial hypertension.*
- *Fusion biopsy – use of MRI–TRUS fusion-guided biopsy technique (reference: standard biopsy).*
- *Upgrading – the presence of pathological upgrading (higher ISUP grade group in final histopathology compared to biopsy).*
- *Statistical significance was defined as a p-value < 0.05.*